ChromaDex Corporation Reports First Quarter 2024 Financial Results
ChromaDex Corporation (CDXC)
NASDAQ:AMEX Investor Relations:
investors.chromadex.com
Company Research
Source: Business Wire
Total net sales of $22.2 million, gross margin of 60.7%, a net loss of $0.5 million and a positive Adjusted EBITDA of $0.7 million for the three months ended March 31, 2024. Reiterated full year outlook including net sales growth of at least 16%. LOS ANGELES--(BUSINESS WIRE)--ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the first quarter of 2024.First Quarter 2024 Financial and Recent Operational HighlightsTotal net sales were $22.2 million, with $17.4 million from Tru Niagen®.Solid gross margin of 60.7%, an increase of 80 basis points, compared to 59.9% from the prior year quarter.Sales and marketing expense as a percentage of net sales was 30.4%, an improvement of 450 basis points, compared to 34.9% from the prior year quarter.Total operating expenses decreased $1.3 million while increasing investments in research and development initiatives.Net loss was $0.5 million or $(0.01) per share, a $1.4 million improvement, or $0.02 per share, from the prior year q
Show less
Read more
Impact Snapshot
Event Time:
CDXC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CDXC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CDXC alerts
High impacting ChromaDex Corporation news events
Weekly update
A roundup of the hottest topics
CDXC
News
- ChromaDex Corporation (NASDAQ:CDXC) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- ChromaDex Co. (NASDAQ: CDXC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.MarketBeat
- ChromaDex Corporation Reports First Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- An Intrinsic Calculation For ChromaDex Corporation (NASDAQ:CDXC) Suggests It's 43% Undervalued [Yahoo! Finance]Yahoo! Finance
- ChromaDex's NIAGEN® (Patented Nicotinamide Riboside, NR), the Most Efficient and High-Quality NAD+ Precursor, Featured in New Solgar® Cellular Nutrition Cellular Energy Supplement [Yahoo! Finance]Yahoo! Finance
CDXC
Earnings
- 5/8/24 - Beat
CDXC
Analyst Actions
- 5/9/24 - HC Wainwright
CDXC
Sec Filings
- 5/8/24 - Form 8-K
- 5/8/24 - Form 10-Q
- 4/25/24 - Form ARS
- CDXC's page on the SEC website